Literature DB >> 21948117

NLRP7 and the genetics of post-molar choriocarcinomas in Senegal.

Rima Slim1, Philippe Coullin, Ange-Lucien Diatta, Wafaa Chebaro, David Courtin, Sonia Abdelhak, Andre Garcia.   

Abstract

Gestational choriocarcinomas are malignant tumors of trophoblastic cells that affect 5-25% of women with sporadic hydatidiform moles (HMs) depending on countries and studies. Nucleotide binding and oligomerization domain-like receptor protein 7 (NLRP7) is a major gene responsible for recurrent HMs and recently mutations in this gene have also been shown in 13% of women with sporadic, non-recurrent  moles. To investigate the role of NLRP7 in the genetic susceptibility for the malignant degeneration of moles, we sequenced its 11 exons in 43 Senegalese patients with post-molar choriocarcinomas. We report the presence of three novel NLRP7 variants that were found only in patients but not in 100 controls from the Senegalese general population, 100 controls from the Tunisian general population, and 100 controls from the Canadian population. In addition, this analysis revealed significant differences in the frequencies of four non-synonymous NLRP7 variants between European and Senegalese controls with the biggest difference being for variant G487E present at a minor allele frequency of 3.5% in Europeans, 18.1% in Tunisians and 45.6% in Senegalese. Comparing human NLRP7 and its paralog, NLRP2, with their mammalian counterparts revealed that allele E at position 487 is most likely the ancestral allele that was acquired in Africa but driven to low frequencies in Europeans and Asians due to migration, population bottlenecks and selective pressures. This study is the first attempt to investigate the role of NLRP7 in choriocarcinomas and highlights the higher frequencies of NLRP7 variants in the general Senegalese and Tunisian populations both known to have higher frequencies of moles and choriocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21948117     DOI: 10.1093/molehr/gar060

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  7 in total

1.  Report of four new patients with protein-truncating mutations in C6orf221/KHDC3L and colocalization with NLRP7.

Authors:  Ramesh Reddy; Elie Akoury; Ngoc Minh Phuong Nguyen; Omar A Abdul-Rahman; Christine Dery; Neerja Gupta; William P Daley; Asangla Ao; Hanene Landolsi; Rosemary Ann Fisher; Isabelle Touitou; Rima Slim
Journal:  Eur J Hum Genet       Date:  2012-12-12       Impact factor: 4.246

2.  No evidence for mutations in NLRP7 and KHDC3L in women with androgenetic hydatidiform moles.

Authors:  Sangeetha Mahadevan; Shu Wen; Alfred Balasa; Gary Fruhman; Julio Mateus; Andrew Wagner; Tarek Al-Hussaini; Ignatia B Van den Veyver
Journal:  Prenat Diagn       Date:  2013-10-04       Impact factor: 3.050

3.  Variable Number Tandem Repeat (VNTR) Genotyping of Hydatidiform Mole in Iranian Patients.

Authors:  Zahra Pakzad; Hossein Mozdarani; Narges Izadi-Mood; Shirin Niromanesh
Journal:  Avicenna J Med Biotechnol       Date:  2014-10

Review 4.  Understanding and management of gestational trophoblastic disease.

Authors:  Fen Ning; Houmei Hou; Abraham N Morse; Gendie E Lash
Journal:  F1000Res       Date:  2019-04-10

Review 5.  Role of NLRP7 in Normal and Malignant Trophoblast Cells.

Authors:  Roland Abi Nahed; Maya Elkhoury Mikhael; Deborah Reynaud; Constance Collet; Nicolas Lemaitre; Thierry Michy; Pascale Hoffmann; Frederic Sergent; Christel Marquette; Padma Murthi; Tiphaine Raia-Barjat; Nadia Alfaidy; Mohamed Benharouga
Journal:  Biomedicines       Date:  2022-01-24

6.  NLRP7 and the Genetics of Hydatidiform Moles: Recent Advances and New Challenges.

Authors:  Rima Slim; Evan P Wallace
Journal:  Front Immunol       Date:  2013-08-20       Impact factor: 7.561

7.  Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma.

Authors:  Yu Lei; Vivian W Y Lui; Jennifer R Grandis; Ann Marie Egloff
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.